Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Summary not available.
Evolent Health (NYSE: EVH) has partnered with Florida Blue Medicare to provide comprehensive oncology specialty management services through its subsidiary, New Century Health. This collaboration aims to manage the cost and quality of oncology care for 125,000 Medicare Advantage members across Florida's network of 1,000 physicians in 67 counties. The initiative focuses on evidence-based clinical pathways and aligned payment models to enhance patient outcomes and reduce costs. Full health plan operations are set to begin on January 1, 2021.
Evolent Health (NYSE: EVH) reported its Q3 2020 results with a revenue of $264.6 million, marking a 20.2% year-over-year increase. Despite the revenue growth, the company faced a net loss of $(37.3) million. Adjusted EBITDA improved to $12.7 million from $3.3 million in Q3 2019. The company announced new partnerships and completed the Passport Health Plan asset sale, enhancing operational efficiencies. Evolent has a cash position of $387 million as of September 30, 2020, and aims to optimize capital allocation for long-term shareholder value.
Evolent Health (NYSE: EVH) will release its third quarter 2020 operating results on November 5, 2020, after market close. Following the release, a conference call will be held at 5:00 p.m. Eastern Time. Investors can join the call by dialing 855.940.9467 or 412.317.6034 for international participants. The call will include details about Evolent's clinical and administrative solutions aimed at enhancing health care affordability and quality. An audio replay will be available on Evolent's investor relations website for one week post-call.
Evolent Health (NYSE: EVH) hosted a virtual Investor and Analyst Day on September 29, 2020, presenting its strategy to enhance shareholder value and operational updates. The Company targets approximately 30% year-over-year adjusted services revenue growth for 2020 and aims for mid-teens annual growth in the medium term. Key announcements include partnerships with Physicians Accountable Care of Utah and Tar River Health Alliance, cost-cutting measures targeting $20-25M in SG&A expenses for 2021, and a focus on achieving a mid-teens Adjusted EBITDA margin. Adjusted Revenue guidance for Q3 2020 is set between $258M-272M.
Evolent Health (NYSE: EVH) will hold its annual Investor and Analyst Day on September 29, 2020, from 10:00 a.m. ET to 12:30 p.m. ET virtually. Interested participants can register and find the live webcast on the company's investor relations website. A replay will also be available post-event. Evolent Health specializes in clinical and administrative solutions to enhance health care affordability and simplicity, serving a diverse range of payers and providers nationwide. The company is recognized for its innovative approaches and quality health solutions.
Evolent Health (NYSE: EVH) will have its CEO Frank Williams, President Seth Blackley, and CFO John Johnson participate in the Baird 2020 Global Healthcare Conference on September 10, 2020, at 9:05 a.m. ET. A live webcast can be accessed through the investor relations section of Evolent's website. Evolent Health specializes in clinical and administrative solutions aimed at improving healthcare quality and affordability, serving a broad base of payers and providers. The company is recognized for its population health program accreditation.
Evolent Health (NYSE: EVH) announced that CEO Frank Williams, President Seth Blackley, and CFO John Johnson will present at two upcoming investor conferences. The presentations will take place at the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 10:40 a.m. ET and at the Baird 2020 Global Healthcare Conference on September 10, 2020, at 9:05 a.m. ET. Evolent Health specializes in health care solutions that improve health affordability and management, serving a national base of leading payers and providers.
Evolent Health (NYSE: EVH) announced a significant financial maneuver involving the issuance of $117 million principal amount of 3.50% Convertible Senior Notes due 2024. This issuance includes $84.2 million in exchange for existing 2.00% Convertible Senior Notes due 2021, alongside $32.8 million generated through cash subscriptions. Expected net proceeds are estimated at $27.4 million. Following this transaction, $26.7 million of the 2021 Notes will remain outstanding. The new notes will be convertible into cash or Evolent's Class A common stock at an initial price of approximately $18.23 per share, representing a 30% premium over the stock's closing price on August 13, 2020.
Evolent Health (EVH) reported a 24.3% increase in GAAP revenue, reaching $238.6 million for Q2 2020 compared to Q2 2019. Despite this growth, the company recorded a net loss of $(203.5) million, impacted by a non-cash goodwill impairment of $215.1 million. Adjusted EBITDA stood at $9.0 million, showcasing operational improvements. Evolent also added two new partners and anticipates over 30% revenue growth in its Services business for the year, alongside a focus on margin enhancement. There will be a change in leadership with Seth Blackley being promoted to CEO on October 1, 2020.
FAQ
What is the current stock price of Evolent Health (EVH)?
What is the market cap of Evolent Health (EVH)?
